Mesothelioma Life Expectancy without Treatment| Impacting Factors

If you want to increase your mesothelioma life expectancy, explore treatment options with an experienced specialist.

Mesothelioma is a rare disease, and a general oncologist may not be equipped with the background or knowledge to successfully fight the disease. Our patient support team is available to contact an experienced doctor.

Some important factors affecting the Mesothelioma Life Expectancy of the patient include:

Location: The place where the disease originated is often the first factor to determine a person’s life expectancy. People with peritoneal mesothelioma (located in the abdomen) often have the best mesothelioma life expectancy, which can be several years or more. Pleural mesothelioma (located in the lungs) carries a life expectancy of one or two years. Pericardial mesothelioma (heart) is the worst prognosis.

Cell type: The type of cells that make up a patient’s mesothelioma determines how fast their disease will spread. Sarcomatoid cells, which are rare, spread most rapidly. The epithelial cells, which are the most common, spread the slowest. Biphasic cells contain sarcomatoid and epithelioid cells, so life expectancy varies.

Stage: The stage of mesothelioma of a patient is a way of classifying how advanced it is. The patient has a better life expectancy with less advanced mesothelioma. The life expectancy of early-stage mesothelioma is close to 21 months while the late stage is closer to 12 months.

Impacting Factors

Some factors affect life expectancy to a great extent; You can limit the impact of these factors on your life expectancy by receiving specialized treatment from an experienced physician.

Mesothelioma stages

The stage of your disease indicates where the mesothelioma has spread. The longer the disease spreads, the more advanced and later it becomes. The life expectancy of a patient is higher in the earlier stages. In the earlier stages of the disease, the patient has more effective treatment options.

Doctors diagnose a patient’s stage of pleural mesothelioma as stage 4-4, stage 4 being the most advanced stage. There is currently no accepted staging system for peritoneal mesothelioma, so doctors diagnose these patients as having either localized or advanced stage mesothelioma.

The following list describes how doctors diagnose the stage of pleural mesothelioma:

  • Stage 1: Localization occurs at the point of origin of cancer.
  • Stage 2: Cancer has spread to the lungs, part of the diaphragm and nearby lymph nodes.
  • Stage 3: Cancer has spread to one side of the chest, the chest wall, esophagus and more lymph nodes.
  • Stage 4: Cancer has spread to both sides of the chest, affecting other organs, blood and bone cells.

While the stage of your disease may help determine your life expectancy, it is important to remember that current statistics are based on the average life span of patients with mesothelioma. These averages include patients who did not receive treatment from a specialist; Therefore, the right treatment can improve your life expectancy.

According to the American Cancer Society, some life expectancies depending on the stage of mesothelioma are:

  • The life expectancy of those patients who are at the stage of 1 or 2 pleural Mesothelioma has 19 to 21 months.
  • Patients with stage 3 or 4 pleural mesothelioma have an average life expectancy of 16 months.
  • Patients with peritoneal mesothelioma who receive surgical treatment often have a life expectancy of more than 5 years.

Mesothelioma diagnosed in the early stage is better than treatments such as surgery or chemotherapy. In fact, with the right treatment, the life expectancy of a patient suffering from stage 1 mesothelioma can range from 30 to 40 months – more than 2 times the average life expectancy of all patients. So keep you updated if you want a treatment

Cell type

Mesothelioma cell type greatly influences your life expectancy. There are three cell types: Epithelioid cells, Sarcomatoid, and Biphasic cells. Each cell type behaves – and reacts to treatment – differently. The doctor determines the tumour cell type when you are diagnosed. Identifying the cell type helps make them the most effective course of treatment for your diagnosis.

The epithelial cells are egg-shaped and stick to each other as they spread. As a result, they spread slowly, making epithelioid mesothelioma the most curable cell type with the best pathogen. The average life expectancy of a patient with epithelial mesothelioma ranges from 12 to 27 months.

Sarcomatoid cells are spindle-shaped and spread quickly to other parts of the body – their speed making them less responsive to treatment. The average life expectancy of a patient with sarcomatoid mesothelioma is 7 to 18 months.

Biphasic tumours consist of both epithelial and sarcomatoid cells. The ratio of these two cell types determines the effect of biphasic mesothelioma on life expectancy. More epithelial cells extend mesothelioma life expectancy because epithelial cells slowly spread and respond better to treatment. The average life expectancy of a biphasic mesothelioma patient with biphasic mesothelioma ranges from 8 to 21 months.

Mesothelioma site

Mesothelioma site also has an effect on mesothelioma life expectancy. Where the tumour originates – the lining of the lungs, abdomen or heart – determines the treatment options available to you.

Pleural mesothelioma arises in the lining of the lungs, the pleura. The average life expectancy of most patients with mesothelioma at this site ranges from 4 to 18 months. You have more treatment options that extend your life if you are diagnosed with pleural epithelium because doctors have more experience in treating it. This type of mesothelioma accounts for 75% of all diagnosed cases.

Peritoneal Mesothelioma arises in the lining of the abdomen, peritoneum, and has the best life expectancy. The average life expectancy of patients diagnosed with peritoneal epithelium is 12 months, although several studies have shown that performing cellular therapy with HIPEC has extended the life expectancy of some patients to 5 years and beyond.

Pericardial mesothelioma arises in the protective lining of the heart, pericardium. It is rare, accounting for about 1% of all diagnoses. The life expectancy of patients with pericardial mesothelioma is 6 months. Pericardial mesothelioma has limited treatment options because its scarcity has given doctors little opportunity to develop new treatments.

A treatment that prolongs life


Surgery is the most effective way for mesothelioma patients to extend life expectancy. There are many surgical options for pleural mesothelioma and peritoneal mesothelioma. If your doctor says you are not eligible for surgical treatment, get a second opinion from another specialist in mesothelioma.

There are two surgeries for pleural mesothelioma patients: extracapsular lung resection (EPP) and pleural resection with exfoliation (P / D). One study reported that treatment with EPP increased the overall patient survival rate to about 27.5 months. (P / D) – A less invasive procedure for patients with pleural mesothelioma – produced results similar to EPP, which extended the survival rate of mesothelioma patients to about 20 months.

Cellular surgery with intraperitoneal chemotherapy (HIPEC) is the most effective surgical option for peritoneal mesothelioma. There are reports that patients increase their life expectancy to more than 7 years with this treatment.

Multimodal therapy

Multimodal therapy is a combination of two or more treatment options, including surgery, chemotherapy, and radiotherapy. In general, the use of more than one treatment has improved the life expectancy of patients.

According to some recent studies, pleural mesothelioma patients who have EPP along with chemotherapy and radiotherapy faced an average survival rate of 13 to 23.9 months. Those with a multimodal treatment combining P / D with chemotherapy and radiotherapy resulted in a better survival rate of up to 30 months.

Cytoreduction with HIPEC is also a form of multimodal therapy. It is a combination of surgery to remove abdominal tumours and hot chemotherapy applied directly to the abdominal cavity that kills microscopic cancer cells after the operation.

Emerging treatments

The emerging treatments in clinical trials are developed and tested by medical researchers and doctors who find better ways to treat patients. If you are diagnosed with stage III or IV stage of mesothelioma, you may not be eligible for traditional treatments, such as EPP or P / D. However, you can benefit from the emerging treatments that researchers are testing in clinical trials. These are the treatments immunotherapy, gene therapy, and photo-dynamic therapy.